Anti-CD89 x Anti-EGFR Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD89 and anti-EGFR parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.
There are currently no customer reviews or questions for Anti-CD89 x Anti-EGFR Bispecific Antibody (IgG-IgG) (BSIG-132). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS